Showing 68,921 - 68,940 results of 68,946 for search '"hematology"', query time: 0.62s Refine Results
  1. 68921

    A comparison of cisplatin cumulative dose and cisplatin schedule in patients treated with concurrent chemo-radiotherapy in nasopharyngeal carcinoma by Mete Gundog, Hatice Basaran, Oktay Bozkurt, Celalettin Eroglu

    Published 2020-11-01
    “…When toxicities were evaluated, such as hematological toxicity, dermatitis, mucositis, nausea and vomiting, there were no statistically significant differences between cumulative dose of cisplatin groups (<200 mg/m2 and ≥200 mg/m2) and chemotherapy schedules (3-weekly and weekly). …”
    Get full text
    Article
  2. 68922

    Intoxicação por veneno de cobra: necrose symetrica da cortex renal: uremia by A. Penna de Azevedo, J. de Castro Teixeira

    Published 1938-01-01
    “…Hyaline and granular casts, as well as white blood cells and kidney cells along with albuminuria, were present. Hematologic examination revealed 11% of hemoglobin; 960.000 red blood cells per cmm., and 5.200 leukocytes per cmm.; differential blood count revealed increase of neutrophil leukocytes along with 74% of segmentated ones. …”
    Get full text
    Article
  3. 68923

    Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital s... by Antonio Cuadrado-Lavín, José Manuel Olmos, José Manuel Cifrian, Teresa Gimenez, Marco Antonio Gandarillas, Mar García-Saiz, Maria Henar Rebollo, Victor Martínez-Taboada, Marcos López-Hoyos, María Carmen Fariñas, Javier Crespo

    Published 2020-06-01
    “…Exclusion criteria: 1) Previous infection with SARS CoV2 (positive coronavirus PCR or positive serology with SARS Cov2 negative PCR and absence of symptoms); 2) Current treatment with hydroxychloroquine or chloroquine; 3) Hypersensitivity, allergy or any contraindication for taking hydroxychloroquine, in the technical sheet; 4) Previous or current treatment with tamoxifen or raloxifene; 5) Previous eye disease, especially maculopathy; 6) Known heart failure (Grade III to IV of the New York Heart Association classification) or prolonged QTc; 7) Any type of cancer (except basal cell) in the last 5 years; 6) Refusal to give informed consent; 8) Evidence of any other unstable or clinically significant untreated immune, endocrine, hematological, gastrointestinal, neurological, neoplastic or psychiatric illness; 9) Antibodies positive for the human immunodeficiency virus; 10) Significant kidney or liver disease; 11) Pregnancy or lactation. …”
    Get full text
    Article
  4. 68924

    Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with transplant‐ineligible multiple myeloma: A network meta‐analysis... by Piechotta, V, Jakob, T, Langer, P, Monsef, I, Scheid, C, Estcourt, L, Ocheni, S, Theurich, S, Kuhr, K, Scheckel, B, Adams, A, Skoetz, N

    Published 2019
    “…<p><strong>Background:</strong><br /> Multiple myeloma is a bone marrow‐based hematological malignancy accounting for approximately two per cent of cancers. …”
    Journal article
  5. 68925

    Assessment of therapeutic and antimocrobial effects of local plants on bacterial diseases in red hybrid tilapia (Oreochromis sp.) by Manaf, Sharifah Raina

    Published 2016
    “…had a synergistic restorative effect on the hematological variables. In conclusion, current study suggested that V. trifolia, S. crispus and A. vera extracts and mixed herbal were effective as growth promoters and bacterial disease treatment in Oreochromis sp. …”
    Get full text
    Thesis
  6. 68926

    Stem Cell Therapy for Congestive Heart Failure by Gunduz E, Akay OM, Birdane A, Gulbas Z

    Published 2011-01-01
    “…We tried to decide the availibility of this route for indications other than hematological diseases. Although trapping of stem cells in the pulmonary vascular bed is a drawback of intravenous route and the question of whether the patient would have been more benefited by intracoronary or intramyocardial route remains unanswered, we think intravenous route may still have some role according to our own experience from this patient. …”
    Get full text
    Article
  7. 68927
  8. 68928

    Inner Ear Hemorrhage : A Cause of Sensorineural Hearing Loss in Leukemia by Nathaniel Yang

    Published 2022-06-01
    “…Inner ear hemorrhage has also been identified in hearing loss related to other hematologic conditions like pernicious anemia, sickle cell anemia, hyperviscosity disorders, and in patients taking anticoagulation drugs like aspirin or warfarin.4 As such, searching for the characteristic imaging findings on MR studies done in these clinical situations would be appropriate. …”
    Get full text
    Article
  9. 68929
  10. 68930
  11. 68931

    PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structur... by Oriana Nanni, Pierluigi Viale, Bernadette Vertogen, Claudia Lilli, Chiara Zingaretti, Caterina Donati, Carla Masini, Manuela Monti, Patrizia Serra, Roberto Vespignani, Veruska Grossi, Annibale Biggeri, Emanuela Scarpi, Francesca Galardi, Lucia Bertoni, Americo Colamartini, Fabio Falcini, Mattia Altini, Ilaria Massa, Raffaella Gaggeri, Giovanni Martinelli

    Published 2020-07-01
    “…All subjects must be aged ≥18 years, male or female, must be willing and able to give informed consent and must not have any contraindications to take hydroxychloroquine (intolerance or previous toxicity for hydroxychloroquine/chloroquine, bradycardia or reduction in heart rhythm with arrhythmia, ischemic heart disease, retinopathy, congestive heart failure with use of diuretics, favism or glucose-6-phosphate dehydrogenase (G6PD) deficiency, diabetes type 1, major comorbidities such as advanced chronic kidney disease or dialysis therapy, known history of ventricular arrhythmia, any oncologic/hematologic malignancy, severe neurological and mental illness, current use of medications with known significant drug-drug interactions, and known prolonged QT syndrome or current use of drugs with known QT prolongation). …”
    Get full text
    Article
  12. 68932

    COVID-19 associated mucormycosis – a recent challenge by Vitorino Modesto dos Santos, Lister Arruda Modesto dos Santos, Taciana Arruda Modesto Sugai

    Published 2023-04-01
    “… Dear Editor, Mucormycosis has been considered an uncommon, life-threatening infection by filamentous fungi living in the soil and vegetable or animal-decomposing matter, causing the infection through superficial lesions and spore inhalation or ingestion, mainly in people with diabetes, malignancy, hematological diseases, or immunosuppression condition.1-12 We read the report by Bhowmik et al.2 about gastric mucormycosis incidentally diagnosed in the autopsy of an Indian man who died of septicemia one week after a road traffic accident. …”
    Get full text
    Article
  13. 68933
  14. 68934

    Severe traumatic brain injury: outcome in patients with diffuse brain injury without surgical lesion managed in Hospital Sultanah Aminah, Johor Bahru an observational study by Liew Boon, Seng

    Published 2009
    “…Patients with polytrauma which caused unstable hemodynamic status, requmng immediate non head surgical intervention and post operative ventilation support, severe underlying medical disorders such as major organ failure, endocrinological or hematological disorder, suspected drug or alcohol intoxication, mentally subnormal, or history of chronic epilepsy before the event of head trauma, or who on arrival had unilateral or bilateral fixed and dilated pupils believed to be due to ongoing herniation, clinically showing absence of brain stem reflexes, with no improvement after resuscitation or failed resuscitation upon admission and patients who had a known history of hemiparesis, or had any other condition that lowered the patient's functional status score were excluded in the study. …”
    Get full text
    Thesis
  15. 68935

    Hurdles overcome in technology transfer for AIET and Positive outcome in Indian patients by Dedeepiya V, Ramanan G, Munirathnam D, Sumana P, Terunuma H, Senthilkumar R, Srinivasan T, Reena H, Preethy S, Abraham S

    Published 2012-01-01
    “…Introduction Cell based immunotherapies have been in practice in Japan for the past two decades with established clinical trials on its efficacy in both solid tumours and hematological malignancies including gastric cancer, ovarian cancer , lung cancer and liver cancer. [1,2,3,4] In India, NCRM has been providing Autologous Immune Enhancement Therapy (AIET) using autologous Natural Killer (NK) cells and activated T Lymphocytes for Cancer since 2005 following the established protocols practiced by the Biotherapy Institute of Japan. …”
    Get full text
    Article
  16. 68936

    Selected Abstracts of the 1st Congress of joint European Neonatal Societies (jENS 2015); Budapest (Hungary); September 16-20, 2015; Session “Circulation, O2 Transport and Haematolo... by --- Various Authors

    Published 2015-09-01
    “…Urlesberger ABS 2. HEMATOLOGIC ABNORMALITIES IN THE FIRST 72 HOURS OF LIFE IN SMALL-FOR-GESTATIONAL-AGE PRETERM NEWBORNS • A. …”
    Get full text
    Article
  17. 68937

    Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial by Ashkan Emadi, Joel V. Chua, Rohit Talwani, Søren M. Bentzen, John Baddley

    Published 2020-10-01
    “…Off-label use of agents such as hydroxychloroquine is not an exclusion criterion, 2) Pregnant or breastfeeding women, 3) Patients with significant liver or renal dysfunction at the time of screening as defined as: 3.1) Direct bilirubin >2.5 mg/dL, 3.2) AST, ALT, or alkaline phosphatase >5x upper limit of normal, 3.3) eGFR ≤30 mL/min or requiring renal replacement therapy, 4) Patients with significant hematologic disorder at screen as defined as: 4.1) Absolute neutrophil count (ANC) <500/μL, 4.2) Platelet <20,000/μL, 4.3) Hemoglobin <7 g/dL, 5) Uncontrolled underlying illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled active seizure disorder, or psychiatric illness/social situations that per site Principal Investigator’s judgment would limit compliance with study requirements, 6) Known allergy to imatinib or its component products, 7) Any other clinical conditions that in the opinion of the investigator would make the subject unsuitable for the study. …”
    Get full text
    Article
  18. 68938
  19. 68939
  20. 68940

    Consenso de leucemia mieloide aguda en México by Luara L. Arana-Luna, Martha Alvarado-Ibarra, Luis G. Silva-Michel, Adrián Morales-Maravilla, María del C. González-Rubio, Lénica A. Chávez-Aguilar, Ma. Fernanda Tena-Iturralde, Liliana Mojica-Balceras, Nidia Zapata-Canto, Patricia Galindo-Delgado, Ma. Raquel Miranda-Madrazo, Alba E. Morales-Hernández, Karina Silva-Vera, Flavio A. Grimaldo-Gómez, Álvaro Hernández-Caballero, Ramón A. Bates-Martín, José L. Álvarez-Vera, Fredy Tepepa-Flores, Óscar Teomitzi-Sánchez, Denisse J. Fermín-Caminero, José A. de la Peña-Celaya, Óscar Salazar-Ramírez, Luz V. Flores-Villegas, Lidia V. Guerra-Alarcón, Faustino Leyto-Cruz, Sergio I. Inclán-Alarcón, Andrea I. Milán-Salvatierra, Yanet Ventura-Enríquez, Uendy Pérez-Lozano, Pamela E. Báez-Islas, Ana L. Tapia-Enríquez, Orlando G. Palma-Moreno, Jocelyn Aguilar-Luevano, Arturo Espinosa-Partida, Luis F. Pérez-Jacobo, Flavio Rojas-Castillejos, Josué I. Ruiz-Contreras, Sergio J. Loera-Fragoso, Jesús E. Medina-Coral, Brenda L. Acosta-Maldonado, Emely J. Soriano-Mercedes, Erick E. Saucedo-Montes, Luis M. Valero-Saldana, Susana G. González-Prieto, Lorena Nava-Villegas, Ana K. Hernández-Colín, Areli E. Hernández-Alcántara, Pedro A. Zárate-Rodríguez, Gregorio Ignacio-Ibarra, Luis A. Meillón-García, Karla A. Espinosa-Bautista, Cindy Ledesma-de la Cruz, Diego M. Barbosa-Loría, Carolina García-Castillo, Carolina Balderas-Delgado, Álvaro Cabrera-García, Juan M. Pérez-Zúñiga, Eleazar Hernández-Ruiz, Atenas Villela-Peña, Sue Cynthia Gómez Cortés, Hilda Romero-Rodelo, Katheryn B. Garzón-Velásquez, Cristina Serrano-Hernández, Annel Martínez-Ríos, Ma. Luisa Pedraza-Colín, Jorge A. Martínez-Coronel, Iris M. Narváez-Davalos, Alinka S. García-Camacho, Laura E. Merino-Pasaye, Carolina Aguilar-Andrade, Juan A. Aguirre-Domínguez, Pedro G. Guzmán-Mera, Elizabeth Delgado-de la Rosa, Perla E. Flores López, Lilia L. González-Aguirre, Edgar M. Ramírez-Alfaro, Heidi Vera-Calderón, Ma. Lizeth Meza-Dávalos, Juan Murillo-Cruz, Yayra M. Pichardo-Cepín, Eva F. Ramírez-Romero

    Published 2022-01-01
    Get full text
    Article